Moderna marks mRNA progress in R&D update
US biotech Moderna (Nasdaq: MRNA) has spent much of the last couple of years banging the drum about the potential of its mRNA platform beyond producing the COVID-19 vaccine that brought the company multi-billion dollar sales and global acclaim.
The company used its latest annual R&D day on Wednesday to do so again, timed to coincide with news that Moderna’s flu vaccine, mRNA-1010, has met its primary endpoint in a Phase III trial. Moderna's shares were up 5.8% at $111.45 in mid-morning trading.
"We look forward to product launches in our oncology, latent, rare and infectious disease franchises"Chief executive Stéphane Bancel said: “Our mRNA platform is working. With today’s positive Phase III flu results, along with previous results in COVID-19 and RSV, we are now three for three on advancing respiratory disease programs to positive Phase III data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze